CAI

Caris Life Sciences, Inc. (CAI) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Caris Life Sciences, Inc. is a patient-centric AI TechBio company focused on precision medicine, primarily in oncology. The company operates as a single segment, offering molecular profiling services (MI Profile, Caris Assure) and pharma research and development services. As of the reporting date, the company had approximately 1.07 million cases in its clinico-genomic dataset.

Key Financial Metrics

Note: Debt figures reflect the 2023 Term Loan outstanding as of March 31, 2026, prior to refinancing.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 78.8% year-over-year to $216.2 million, driven primarily by an 84.8% increase in molecular profiling services revenue ($210.8 million). This was fueled by higher clinical case volumes (52,800 cases vs. 45,900) and higher average selling prices due to the launch of MI Cancer Seek.
• Profitability: The company achieved a significant turnaround, moving from a net loss of $102.6 million in Q1 2025 to a net loss of only $0.5 million in Q1 2026. Operating income improved from a loss of $58.0 million to a profit of $5.3 million.
• Cash Flow: Operating cash flow swung from a use of $31.3 million to a generation of $32.9 million. Free cash flow improved from $(34.0) million to $22.5 million.
• Interest Income: Interest income surged to $6.8 million (from $0.5 million) due to higher cash balances earning interest.
• Debt Refinancing: On April 1, 2026 (subsequent to the period end), the company fully repaid its $400 million 2023 Term Loan and entered a new financing agreement with a $400 million initial term loan maturing in 2031.

Outlook, Risks, and Management Commentary

• Guidance & Outlook: Management expects expenses to increase as the company invests in new solutions, expands its organization, and increases marketing efforts. The company anticipates continued growth in profiling volumes driven by the commercial launch of Caris Assure and MI Cancer Seek.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to a previously reported material weakness regarding a lack of sufficient qualified accounting resources. Remediation efforts are ongoing.
• Legal Proceedings: The company is cooperating with a U.S. Department of Justice investigation (Civil Investigative Demand) regarding compliance with Medicare's "14-day rule" for date of service. The outcome is uncertain.
• Liquidity: With $823.4 million in cash and equivalents and strong operating cash flow, management believes current resources are sufficient to fund operations for at least the next 12 months.

Key Facts for Investor Verification

• Debt Restructuring: Verify the terms and interest rates of the new 2026 Financing Agreement entered into on April 1, 2026, which replaced the 2023 Term Loan.
• Internal Control Remediation: Monitor progress on remediating the material weakness in internal controls over financial reporting to ensure future reporting reliability.
• Regulatory Investigation: Track the status of the DOJ investigation regarding the Medicare 14-day rule and potential financial or reputational impact.
• Reimbursement Trends: Assess the sustainability of the increased average selling price (ASP) and reimbursement rates for MI Profile and Caris Assure, which drove the revenue surge.
• Case Volume Growth: Confirm the continued growth in clinical case volumes (52,800 in Q1 2026) to validate the revenue trajectory.